Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

BACKGROUND: In melanoma, dysregulation of the MAPK pathway, usually via BRAF(V600) or NRAS(Q61) somatic mutations, leads to constitutive ERK signaling. While BRAF inhibitors are initially effective for BRAF-mutant melanoma, no FDA-approved targeted therapies exist for BRAF-inhibitor-resistant BRAF(V...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wong, Deborah JL, Robert, Lidia, Atefi, Mohammad S, Lassen, Amanda, Avarappatt, Geetha, Cerniglia, Michael, Avramis, Earl, Tsoi, Jennifer, Foulad, David, Graeber, Thomas G, Comin-Anduix, Begonya, Samatar, Ahmed, Lo, Roger S, Ribas, Antoni
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2014
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4155088/
https://ncbi.nlm.nih.gov/pubmed/25142146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-13-194
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados